CY1124546T1 - Υγρο σκευασμα για εισπνοη που περιεχει rpl554 - Google Patents
Υγρο σκευασμα για εισπνοη που περιεχει rpl554Info
- Publication number
- CY1124546T1 CY1124546T1 CY20211100720T CY211100720T CY1124546T1 CY 1124546 T1 CY1124546 T1 CY 1124546T1 CY 20211100720 T CY20211100720 T CY 20211100720T CY 211100720 T CY211100720 T CY 211100720T CY 1124546 T1 CY1124546 T1 CY 1124546T1
- Authority
- CY
- Cyprus
- Prior art keywords
- rpl554
- preparation containing
- inhalation preparation
- particle size
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Η παρούσα εφεύρεση αφορά μια υγρή φαρμακευτική σύνθεση κατάλληλη για χορήγηση με εισπνοή η οποία περιλαμβάνει ένα αραιωτικό και ένα εναιώρημα σωματιδίων 9,10-διμεθοξυ-2-(2,4,6-τριμεθυλοφαινυλιμινο)-3-(Ν-καρβαμοϋλ-2-αμινοαιθυλ)-3,4,6,7-τετραϋδρο-2Η-πυριμιδο[6,1-a]ισοκινολιν-4-όνης (RPL554) ή ενός φαρμακευτικώς αποδεκτού άλατος αυτής, όπου τα σωματίδια του RPL554 έχουν κατανομή μεγέθους σωματιδίων με τιμή Dv50 (μέσο μέγεθος σωματιδίων κατά όγκο) από περίπου 0,2 μm έως περίπου 5 μm• και η σύνθεση περιέχει φωσφορικό ρυθμιστικό σε συγκέντρωση από 0 έως 5 mg/mL. Περιγράφεται επίσης μια υγρή φαρμακευτική σύνθεση σύμφωνα με την εφεύρεση για χρήση στη θεραπεία ανθρώπινου ή ζωικού οργανισμού.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1416274.7A GB201416274D0 (en) | 2014-09-15 | 2014-09-15 | Formulation |
GBGB1504662.6A GB201504662D0 (en) | 2015-03-19 | 2015-03-19 | Formulation |
PCT/GB2015/052668 WO2016042313A1 (en) | 2014-09-15 | 2015-09-15 | Liquid inhalation formulation comprising rpl554 |
EP15770593.0A EP3193835B1 (en) | 2014-09-15 | 2015-09-15 | Liquid inhalation formulation comprising rpl554 |
EP17207623.4A EP3332767B1 (en) | 2014-09-15 | 2015-09-15 | Liquid inhalation formulation comprising rpl554 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124546T1 true CY1124546T1 (el) | 2022-07-22 |
Family
ID=54196992
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100455T CY1120264T1 (el) | 2014-09-15 | 2018-05-03 | Υγρο σκευασμα για εισπνοη που περιεχει rpl554 |
CY20191100622T CY1121698T1 (el) | 2014-09-15 | 2019-06-18 | Υγρο σκευασμα για εισπνοη που περιεχει rpl554 |
CY20211100720T CY1124546T1 (el) | 2014-09-15 | 2021-08-10 | Υγρο σκευασμα για εισπνοη που περιεχει rpl554 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100455T CY1120264T1 (el) | 2014-09-15 | 2018-05-03 | Υγρο σκευασμα για εισπνοη που περιεχει rpl554 |
CY20191100622T CY1121698T1 (el) | 2014-09-15 | 2019-06-18 | Υγρο σκευασμα για εισπνοη που περιεχει rpl554 |
Country Status (27)
Country | Link |
---|---|
US (2) | US9956171B2 (el) |
EP (3) | EP3332767B1 (el) |
JP (2) | JP6860477B2 (el) |
KR (1) | KR102379309B1 (el) |
CN (3) | CN106794157B (el) |
AU (3) | AU2015316592B2 (el) |
CA (1) | CA2959943C (el) |
CY (3) | CY1120264T1 (el) |
DK (3) | DK3494962T3 (el) |
ES (3) | ES2730810T3 (el) |
HK (1) | HK1249415B (el) |
HR (3) | HRP20180833T1 (el) |
HU (3) | HUE038433T2 (el) |
IL (1) | IL250895B (el) |
LT (3) | LT3193835T (el) |
MX (1) | MX2017003102A (el) |
MY (1) | MY196072A (el) |
NO (1) | NO3193835T3 (el) |
NZ (3) | NZ767296A (el) |
PH (1) | PH12017500479B1 (el) |
PL (3) | PL3332767T3 (el) |
PT (3) | PT3332767T (el) |
RS (3) | RS58897B1 (el) |
RU (1) | RU2699995C2 (el) |
SG (1) | SG11201701854WA (el) |
SI (3) | SI3193835T1 (el) |
WO (1) | WO2016042313A1 (el) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2682105T3 (es) | 2014-05-12 | 2018-09-18 | Verona Pharma Plc | Nuevo tratamiento |
LT3193835T (lt) * | 2014-09-15 | 2018-06-11 | Verona Pharma Plc | Skysta inhaliuojama vaisto forma, apimanti rpl554 |
GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
CN107849092A (zh) | 2015-07-24 | 2018-03-27 | 豪夫迈·罗氏有限公司 | Bace1抑制剂肽 |
GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
GB2578093B (en) | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤 |
GB201911517D0 (en) | 2019-08-12 | 2019-09-25 | Verona Pharma Plc | Pharmaceutical composition |
CN114929700A (zh) * | 2020-01-15 | 2022-08-19 | 正大天晴药业集团股份有限公司 | 三并环类pde3/pde4双重抑制剂化合物的药物组合物 |
GB202002786D0 (en) | 2020-02-27 | 2020-04-15 | Verona Pharma Plc | Liquid pharmaceutical composition |
GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
WO2024033627A1 (en) * | 2022-08-08 | 2024-02-15 | Verona Pharma Plc | Liquid pharmaceutical composition |
WO2024033625A1 (en) * | 2022-08-08 | 2024-02-15 | Verona Pharma Plc | Ensifentrine (rpl-554) for increasing trough lung function |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9410222D0 (en) * | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
AU9674398A (en) | 1997-10-09 | 1999-05-03 | Schering Corporation | Mometasone furoate suspensions for nebulization |
SE9704186D0 (sv) | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
US6630169B1 (en) * | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
ES2208310T3 (es) * | 1999-03-31 | 2004-06-16 | Vernalis Limited | Derivados de pirimido(6,1-a) isoquinolin-4-ona. |
GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
GB0122031D0 (en) * | 2001-09-12 | 2001-10-31 | Pfizer Ltd | Use of pde4 inhibitors in a dry powder inhaler |
US7579505B2 (en) | 2004-12-17 | 2009-08-25 | Cipla Limited | Crystalline levosalbutamol sulphate and polymorphic forms thereof |
ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
CN102947300B (zh) | 2010-06-22 | 2016-09-21 | 奇斯药制品公司 | 生物碱氨基酯衍生物及其药物组合物 |
ES2483801T3 (es) | 2010-08-09 | 2014-08-07 | Verona Pharma Plc | Forma cristalina de compuesto de pirmido[6,1-a]isoquinolin-4-ona |
EP2717855A4 (en) * | 2011-06-07 | 2014-11-12 | Parion Sciences Inc | PROCESSING METHODS |
US8945605B2 (en) * | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
EP2647627A1 (en) * | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
WO2014037727A1 (en) * | 2012-09-06 | 2014-03-13 | Verona Pharma Plc | Carcainium salts |
HUE038899T2 (hu) * | 2013-03-15 | 2018-12-28 | Verona Pharma Plc | Gyógyszer kombináció |
ES2682105T3 (es) | 2014-05-12 | 2018-09-18 | Verona Pharma Plc | Nuevo tratamiento |
LT3193835T (lt) * | 2014-09-15 | 2018-06-11 | Verona Pharma Plc | Skysta inhaliuojama vaisto forma, apimanti rpl554 |
GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
-
2015
- 2015-09-15 LT LTEP15770593.0T patent/LT3193835T/lt unknown
- 2015-09-15 PT PT17207623T patent/PT3332767T/pt unknown
- 2015-09-15 RS RS20190765A patent/RS58897B1/sr unknown
- 2015-09-15 HU HUE15770593A patent/HUE038433T2/hu unknown
- 2015-09-15 PL PL17207623T patent/PL3332767T3/pl unknown
- 2015-09-15 CN CN201580053062.1A patent/CN106794157B/zh active Active
- 2015-09-15 WO PCT/GB2015/052668 patent/WO2016042313A1/en active Application Filing
- 2015-09-15 EP EP17207623.4A patent/EP3332767B1/en active Active
- 2015-09-15 NZ NZ767296A patent/NZ767296A/en unknown
- 2015-09-15 ES ES17207623T patent/ES2730810T3/es active Active
- 2015-09-15 KR KR1020177006862A patent/KR102379309B1/ko active IP Right Grant
- 2015-09-15 RS RS20180519A patent/RS57227B1/sr unknown
- 2015-09-15 CN CN202010090019.5A patent/CN111249260B/zh active Active
- 2015-09-15 DK DK19152629.2T patent/DK3494962T3/da active
- 2015-09-15 CA CA2959943A patent/CA2959943C/en active Active
- 2015-09-15 LT LTEP17207623.4T patent/LT3332767T/lt unknown
- 2015-09-15 EP EP15770593.0A patent/EP3193835B1/en active Active
- 2015-09-15 ES ES15770593.0T patent/ES2670025T3/es active Active
- 2015-09-15 PT PT191526292T patent/PT3494962T/pt unknown
- 2015-09-15 NZ NZ767295A patent/NZ767295A/en unknown
- 2015-09-15 SG SG11201701854WA patent/SG11201701854WA/en unknown
- 2015-09-15 RS RS20211044A patent/RS62252B1/sr unknown
- 2015-09-15 RU RU2017108432A patent/RU2699995C2/ru active
- 2015-09-15 CN CN201811561721.4A patent/CN110051627A/zh active Pending
- 2015-09-15 AU AU2015316592A patent/AU2015316592B2/en active Active
- 2015-09-15 JP JP2017514346A patent/JP6860477B2/ja active Active
- 2015-09-15 SI SI201530213T patent/SI3193835T1/en unknown
- 2015-09-15 PL PL15770593T patent/PL3193835T3/pl unknown
- 2015-09-15 DK DK17207623.4T patent/DK3332767T3/da active
- 2015-09-15 HU HUE17207623A patent/HUE045303T2/hu unknown
- 2015-09-15 EP EP19152629.2A patent/EP3494962B1/en active Active
- 2015-09-15 SI SI201530774T patent/SI3332767T1/sl unknown
- 2015-09-15 LT LTEP19152629.2T patent/LT3494962T/lt unknown
- 2015-09-15 DK DK15770593.0T patent/DK3193835T3/en active
- 2015-09-15 MX MX2017003102A patent/MX2017003102A/es active IP Right Grant
- 2015-09-15 MY MYPI2017000391A patent/MY196072A/en unknown
- 2015-09-15 SI SI201531657T patent/SI3494962T1/sl unknown
- 2015-09-15 NZ NZ729796A patent/NZ729796A/en unknown
- 2015-09-15 PL PL19152629T patent/PL3494962T3/pl unknown
- 2015-09-15 NO NO15770593A patent/NO3193835T3/no unknown
- 2015-09-15 PT PT157705930T patent/PT3193835T/pt unknown
- 2015-09-15 ES ES19152629T patent/ES2875584T3/es active Active
- 2015-09-15 US US15/509,943 patent/US9956171B2/en active Active
- 2015-09-15 HU HUE19152629A patent/HUE055527T2/hu unknown
-
2017
- 2017-03-02 IL IL250895A patent/IL250895B/en active IP Right Grant
- 2017-03-14 PH PH12017500479A patent/PH12017500479B1/en unknown
-
2018
- 2018-03-21 US US15/927,517 patent/US10945950B2/en active Active
- 2018-05-03 CY CY20181100455T patent/CY1120264T1/el unknown
- 2018-05-25 HR HRP20180833TT patent/HRP20180833T1/hr unknown
- 2018-07-10 HK HK18108909.3A patent/HK1249415B/zh unknown
- 2018-12-20 JP JP2018238014A patent/JP6795574B2/ja active Active
- 2018-12-24 AU AU2018286571A patent/AU2018286571B2/en active Active
-
2019
- 2019-06-18 CY CY20191100622T patent/CY1121698T1/el unknown
- 2019-06-19 HR HRP20191122TT patent/HRP20191122T1/hr unknown
-
2020
- 2020-05-11 AU AU2020203081A patent/AU2020203081B2/en active Active
-
2021
- 2021-06-30 HR HRP20211035TT patent/HRP20211035T1/hr unknown
- 2021-08-10 CY CY20211100720T patent/CY1124546T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124546T1 (el) | Υγρο σκευασμα για εισπνοη που περιεχει rpl554 | |
CY1124675T1 (el) | Σταθερη καθορισμενης δοσης φαρμακευτικη συνθεση που περιλαμβανει μομεταζονη και ολοπαταδινη για ρινικη χορηγηση | |
MY188825A (en) | High-concentration monoclonal antibody formulations | |
BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
SA515361055B1 (ar) | نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون | |
UA107112C2 (en) | Activator of soluble guanylate cyclase | |
NZ741291A (en) | Stabilizing camptothecin pharmaceutical compositions | |
MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
CY1124635T1 (el) | Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα | |
JP2019530706A5 (el) | ||
EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
MX2017012312A (es) | Formulacion estable para administracion parenteral de tapentadol. | |
MX2019005160A (es) | Formulacion farmaceutica. | |
EA202090172A1 (ru) | Суспензия на основе левоклоперастина фендизоата с повышенными растворимостью и ресуспендируемостью | |
CY1120282T1 (el) | Φαρμακευτικη συνθεση κιτρικης σιλδεναφιλης με την μορφη ενος εναιωρηματος για εκ του στοματος χρηση | |
PH12018502195A1 (en) | Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases | |
MX2017004633A (es) | Formulaciones que contienen tiotropio, aminoacidos y acidos, y metodos de estas. | |
EA201990744A1 (ru) | Стабильная лекарственная форма для парентерального введения тапентадола | |
TH174318A (th) | สูตรผสม | |
TH174318B (th) | สูตรผสม | |
MX2019006548A (es) | Composicion para el tratamiento de la osteoartritis. | |
MX2017016423A (es) | Polvos de zolmitriptán para sumunistro pulmonar. | |
EA201790140A1 (ru) | Фармацевтические лекарственные формы |